Prelude Therapeutics CEO Krishna Vaddi's 2021 pay falls 40% to $7M
Prelude Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 29, 2022
Prelude Therapeutics reported fiscal year 2021 executive compensation information on April 29, 2022.
In 2021, four executives at Prelude Therapeutics received on average a compensation package of $3.8M, a 17% decrease compared to previous year.
Average pay of disclosed executives at Prelude Therapeutics
Krishna Vaddi, Chief Executive Officer, received $7M in total, which decreased by 40% compared to 2020. 88% of Vaddi's compensation, or $6.2M, was in option awards. Vaddi also received $266K in non-equity incentive plan and $544K in salary.
Brian Piper, Chief Financial Officer, received a compensation package of $2.9M, which increased by 48% compared to previous year. 87% of the compensation package, or $2.5M, was in option awards.
Peggy Scherle, Chief Scientific Officer, earned $2.6M in 2021, a 2% decrease compared to previous year.
Andrew Combs, EVP and Head of Chemistry, received $2.6M in 2021, which increases by 31% compared to 2020.
Related executives
You may also like
Source: SEC filing on April 29, 2022.